Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Prem Prakash Tripathi 1, 2 , Hamed Arami 3, 4 , Ivneet Banga 5 , Jalaj Gupta 6 and Sonu Gandhi 7 1 CSIR-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata, India 2 IICB-Translational Research Unit of Excellence, Kolkata, India 3 Molecular Imaging Program at Stanford (MIPS), The James H. Clark Center, Stanford University, Stanford, CA, USA 4 Department of Radiology, Stanford University, School of Medicine, Stanford, CA, USA 5 Department of Bioengineering, University of Texas, Arlington, TX, USA 6 Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany 7 DBT-National Institute of Animal Biotechnology (DBT-NIAB), Hyderabad, India Correspondence to: Sonu Gandhi, email: gandhi@niab.org.in Prem Prakash Tripathi, email: prem.tripathi@iicb.res.in Keywords: cell penetrating peptides; cancer targeting; therapy; diagnostic; imaging Received: September 07, 2018 Accepted: November 29, 2018 Published: December 14, 2018 ABSTRACT Delivery of imaging reagents and drugs to tumors is essential for cancer diagnosis and therapy. In addition to therapeutic and diagnostic functionalities, peptides have potential benefits such as biocompatibility, ease to synthesize, smaller size, by-passing off-target side effects, and achieving the beneficial effects with lower-administered dosages. A particular type of peptide known as cell penetrating peptides (CPP) have been predominantly studied during last twenty years as they are not only capable to translocate themselves across membranes but also allow carrier drugs to translocate across plasma membrane, by different mechanisms depending on the CPP. This is of great potential importance in drug delivery systems, as the ability to pass across membranes is crucial to many drug delivery systems. In spite of significant progress in design and application of CPP, more investigations are required to further improve their delivery to tumors, with reduced side-effect and enhanced therapeutic efficacy. In this review, we emphasis on current advancements in preclinical and clinical trials based on using CPP for more efficient delivery of anti-cancer drugs and imaging reagents to cancer tissues and individual cells associated with them. We discuss the evolution of the CPPs-based strategies for targeted delivery, their current status and strengths, along with summarizing the role of CPPs in targeted drug delivery. We also discuss some recently reported diagnostic applications of engineered protease-responsive substrates and activable imaging complexes. We highlight the recent clinical trial data by providing a road map for better design of the CPPs for future preclinical and clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wadia, J. S., Stan, R. V., & Dowdy, S. F. (2004) · Nature Medicine · doi:10.1038/nm996 · Cited by 1,647 · cited 2×
“In one approach pH sensitive domains were introduce in the peptide sequence to disrupt lipid membrane at low pH to felicitate the CPP escape from vesicles [19].”
BackgroundTransvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Self-citationTorchilin, V. P. (2008) · Peptide Science · doi:10.1002/bip.20989 · Cited by 283
Pulford, B., Reim, N., Bell, A., Veatch, J., Forster, G., Bender, H., Meyerett, C., Hafeman, S., Michel, B., Johnson, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011085 · Cited by 85 · cited 1×
“Similar results were also reported by using other peptides such as RVG-9R complexes with siRNA that can cross blood brain barrier and target japanese encephalitis virus [57].”
Result
Cited by
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Xie, J., Bi, Y., Zhang, H., Dong, S., Teng, L., Lee, R. J., & Yang, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00697 · Cited by 466
Gessner, I., & Neundorf, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072536 · Cited by 212
Cell penetrating peptide: A potent delivery system in vaccine development
Hasannejad-Asl, B., Pooresmaeil, F., Takamoli, S., Dabiri, M., & Bolhassani, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072685 · Cited by 40
Advances and prospects of cell-penetrating peptides in tumor immunotherapy
Yang, D., Liu, B., & Sha, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86130-8 · Cited by 31
Computational Insights into Membrane Disruption by Cell-Penetrating Peptides
Catalina-Hernandez, E., Aguilella-Arzo, M., Peralvarez-Marin, A., & Lopez-Martin, M. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01940 · Cited by 18
Identification of PS1/gamma-secretase and glutamate transporter GLT-1 interaction sites
Perrin, F., Sinha, P., Mitchell, S. P. C., Sadek, M., Maesako, M., & Berezovska, O. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107172 · Cited by 3
Metadata
- Authors
- Tripathi, P. P., Arami, H., Banga, I., Gupta, J., & Gandhi, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-12-14
- Volume
- 9
- Issue
- 98
- Pages
- 37252-37267
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2905504720
- Cited by
- 130
- References
- 5
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.